Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).

Autor: Wozniak AJ; Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA. Electronic address: wozniakaj@upmc.edu., Schneider B; Department of Medicine, University of Michigan, Ann Arbor, MI., Kalemkerian GP; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI., Daly B; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Chen W; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Ventimiglia J; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI., Nagasaka M; Division of Hematology/Oncology, Department of Medicine, University of California, Orange, CA., Zauderer MG; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2023 Sep; Vol. 24 (6), pp. 563-567. Date of Electronic Publication: 2023 Apr 07.
DOI: 10.1016/j.cllc.2023.04.004
Databáze: MEDLINE